Astellas Pharma Ltd

Lovett House, Lovett Road, Staines, Middlesex, TW18 3AZ
Telephone: +44 (0)1784 419615
Fax: +44 (0)1784 419583
Summary of Product Characteristics last updated on the eMC: 07/02/2008
SPC Ridaura Tiltab Tablets 3mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/02/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.3       Contraindications

The word 'necrotising' has been deleted.

 

4.4       Special Warnings and Special Precautions for Use

The following paragraphs have been added -

Patients should be cautioned to minimise exposure to ultraviolet light.

 

Auranofin has not been co-administered with other disease modifying agents such as penicillamine, levamisole and chloroquine/hydrochloroquine and, therefore, concomitant use cannot be recommended.

 

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

 

Enterocolitis is a rare but potentially serious side effect, the development of diarrhoea with rectal bleeding or rectal bleeding alone unless rapidly explained otherwise mandates the immediate cessation of therapy.  Patients should be warned to seek medical advice as soon as possible if they develop these symptoms.

 

4.5       Interaction with other Medicinal products and other forms of Interaction

'None stated' has been deleted and the following paragraphs added -

 

Specific experience of interactions with auranofin is lacking. However, the theoretical potential for interaction with gold therapy, both oral and parenteral, should be considered.

 

Concomitant therapy with metal antagonists and potentially nephrotoxic or haemotoxic drugs should be administered with caution. Such drugs include penicillamine, aminoglycosides, amphotericin B, penicillins, phenylbutazone, phenytoin, sulfonamides, NSAIDs, acyclovir and alcohol.

 

Drugs affecting GI motility and those which are highly protein-bound may alter the absorption and binding, respectively, of auranofin.

 

4.8       Undesirable Effects

The following paragraph has been deleted -

Ulcerative enterocolitis has been very rarely reported (<0.01%), as with all gold containing drugs.  Therefore patients with gastrointestinal symptoms should be carefully monitored for the appearance of gastrointestinal bleeding and treatment stopped if this occurs. See table.

 

In the table, the name Ulcerative enterocolitis has been changed to Enterocolitis.  Also Dizziness and Colitis have been added.

Updated on 09/01/2006 and displayed until 07/02/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 05/12/2003 and displayed until 09/01/2006
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
  • Addition of Legal Category
Updated on 13/03/2003 and displayed until 05/12/2003
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 10 (date of (partial) revision of the text
  • Addition of Legal Category
Updated on 24/08/2001 and displayed until 13/03/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 28/01/2000 and displayed until 24/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 28/01/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   auranofin


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk